U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT04846920) titled 'A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)' on April 7.
Brief Summary: The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating doses of belzutifan as second line positive (2L+) treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).
Study Type: Interventional
Condition: Carcinoma, Renal Cell
Intervention: Drug: Belzutifan
40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.
Other Names: * MK-6482
* PT2977
Recruitment Status: Not Yet Recruiting
Sponsor: Merck Sharp & Dohme Co...